Literature DB >> 2339102

Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

H A Semple1, Y K Tam, R T Coutts.   

Abstract

The intravenous and oral dose-dependent pharmacokinetics of hydralazine and the effect of concurrent administration of food with hydralazine in dogs were evaluated for comparison with published human data. Four dogs were given intravenous and oral doses of hydralazine at 0.25, 1.0, 2.5, and 4.0 mg/kg. In addition, the oral 2.5 mg/kg dose was given with a meal. Blood samples were collected at appropriate intervals and analyzed for hydralazine. Pharmacokinetic analysis showed that AUCoral/dose (5552 to 13218 mg-min/ml) and F (0.36 to 0.77) increased significantly with dose, indicating saturation of first-pass metabolism, as is seen in humans. Total-body clearance (70 ml/min/kg) and steady-state volume of distribution (9 L/kg) were similar to human values. The bioavailability of hydralazine in the dog was decreased by 63% when the dose was given with a meal, which is comparable to some human data. It was concluded that the dog may be a useful model in which to study mechanisms of the hydralazine-food interaction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339102     DOI: 10.1023/a:1015830330231

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  The assessment of bioavailability in the presence of nonlinear elimination.

Authors:  S D Hall; C B McAllister; G R Wilkinson
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

2.  Effects of hydralazine on liver blood flow in normovolemic dogs.

Authors:  T Saretok; O Almersjö; B Biber; B Gustavsson; P O Hasselgren
Journal:  Acta Chir Scand       Date:  1984

3.  Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.

Authors:  B Heinzow; H Corbett; S Constantinides; R Bourne; A J McLean
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

4.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

5.  Oral hydralazine therapy for chronic mitral regurgitation in the dog.

Authors:  M D Kittleson; G E Eyster; N B Olivier; L K Anderson
Journal:  J Am Vet Med Assoc       Date:  1983-06-01       Impact factor: 1.936

Review 6.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

7.  Metabolism and disposition of hydralazine-14C in man and dog.

Authors:  J M Lesser; Z H Israili; D C Davis; P G Dayton
Journal:  Drug Metab Dispos       Date:  1974 Jul-Aug       Impact factor: 3.922

8.  Assay for hydralazine as its stable p-nitrobenzaldehyde hydrazone.

Authors:  H A Semple; Y K Tam; S Tin; R T Coutts
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

9.  Hydralazine kinetics after single and repeated oral doses.

Authors:  A M Shepherd; T M Ludden; J L McNay; M S Lin
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

10.  Hydralazine kinetics in hypertensive patients after intravenous administration.

Authors:  T M Ludden; A M Shepherd; J L McNay; M S Lin
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

View more
  4 in total

1.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

Review 2.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

3.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

4.  Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model.

Authors:  Nuzhat Tam-Zaman; Yun K Tam; Soheir Tawfik; Hugh Wiltshire
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.